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Aims: Sacral chordomas are locally aggressive, radio-resistant tumours. Proton therapy has the potential to deliver high radiation doses, which may improve the
therapeutic ratio when compared with conventional radiotherapy. We assessed tumour control and radiation-induced toxicity in a cohort of sacral chordoma
patients treated with definitive or postoperative pencil beam scanning proton therapy.
Methods and materials: Sixty patients with histologically proven sacral chordoma treated between November 1997 and October 2018 at the Paul Scherrer
Institute with postoperative (n ¼ 50) or definitive proton therapy (n ¼ 10) were retrospectively analysed. Only 10 (17%) patients received combined photon
radiotherapy and proton therapy. Survival rates were calculated using the KaplaneMeier actuarial method. The Log-rank test was used to compare different
functions for local control, freedom from distant recurrence and overall survival. Acute and late toxicity were assessed according to the Common Terminology
Criteria for Adverse Events (CTCAE) v5.0.
Results: The median follow-up was 48 months (range 4e186). Local recurrence occurred in 20 (33%) patients. The 4-year local control, freedom from distant
recurrence and overall survival rates were 77%, 89% and 85%, respectively. On univariate analysis, subtotal resection/biopsy (P ¼ 0.02), tumour extension
restricted to bone (P ¼ 0.01) and gross tumour volume >130 ml (P ¼ 0.04) were significant predictors for local recurrence. On multivariate analysis, tumour
extension restricted to bone (P ¼ 0.004) and gross total resection (P ¼ 0.02) remained independent favourable prognostic factors for local recurrence. Twenty-
four (40%), 28 (47%) and eight (11%) patients experienced acute grade 1, 2 and 3 toxicities, respectively. The 4-year late toxicity-free survival was 91%. Two
patients developed secondary malignancies to the bladder 3e7 years after proton therapy.
Conclusions: Our data indicate that pencil beam scanning proton therapy for sacral chordomas is both safe and effective. Gross total resection, tumour volume
<130 ml and tumour restricted to the bone are favourable prognostic factors for local tumour control.
 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
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Chordomas are rare bone tumours, with an incidence of
about 0.8e1 per million per year [1] arising from remnants
of the chorda dorsalis. They arise equally distributed along
the vertebral column from the skull base to the sacro-
coccygeal region [2]. Although usually described as slow-Author for correspondence: D.C. Weber, Center for Proton Therapy, Paul
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Clinical Oncology, https://doi.org/10.1016/j.clon.2021.07.012growing tumours with low metastatic potential, they show
aggressive local growth, leading to impaired neurological
symptoms, which can ultimately lead to death [3]. The
treatment strategy usually consists of maximal tumour
debulking that leaves the patients functionally intact with, if
necessary, sequential staged surgical procedures. Total
resection can often only be achieved at a high functional
cost. As such, less radical surgery that results in tumour
debulking and adjuvant radiation treatment is an appro-
priate strategy if the patients want to minimise post-
operative adverse events and late sequelae. After surgeryAll rights reserved.
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be an important prognostic factor [4e7], recurrence rates are
high [7e11], which has a negative impact on the survival of
these patients with these challenging tumours. The addition
of adjuvant systemic treatment did not improve the prog-
nosis [12], nor did radiation therapy, with moderate doses
up to 60 Gy delivered to these radio-resistant tumours [13].
Onlywith the administration of high radiation therapy doses
(i.e. in the range of 70e78 Gy) can this treatment modality
result in improved local tumour control and overall survival
rates for skull base and extracranial chordoma patients alike
[14,15]. The high radiation conformity and the reduction of
the integral dose by the use of protons has made proton
therapy the standard radiation modality for the manage-
ment of these tumours, with increased tumour control and
reduced toxicity rates [16e18]. At the Paul Scherrer Institute
(PSI), pencil beam scanning (PBS) proton therapy was
developed and delivered for routine clinical use; since 1996
more than 1500 patients [19] have been treated with this
delivery technique. Preliminary results of patients with
extracranial chordomas and chondrosarcomas treated with
PBS proton therapy at our institution have been published
[20e23]. This study was an update of these series, with a
focus on the chordomas of the sacrococcygeal region only,
with a long-term follow-up and an increased patient
number.Materials and Methods
Patient and Tumour Characteristics
Between November 1997 and October 2018, 60 (median
age 59 years; range 28e82) adult patients (male, n ¼ 41;
68%) with histologically proven sacral chordoma were
treated at PSI with PBS proton therapy. Only 10 (17%) pa-
tients received combined photon radiotherapy and proton
therapy, mainly for logistical reasons. Patients’ characteris-
tics are summarised in Table 1. Inoperable, incompletely (R1
or R2) or completely resected (R0) patients with close
margins were included into the study cohort. Most patients
(n ¼ 47; 78%) were treated upfront with surgery and adju-
vant proton therapy (Table 1). The extent of surgical
resection was categorised according to the definition of La
Corte et al. [24] for chordomas as gross total resection if
100% of the chordoma was removed, subtotal resection if
the removed tumour amount was between 99% and 85%
and partial resection if it was <85%. Fifty (83%) patients
underwent surgery and 10 (17%) had a biopsy only. For
those undergoing resection, 33 (66%) underwent gross total
resection. Twelve patients had two or three surgeries (Table
1). Only one (2%) patient had metal implants for stabilisa-
tion. This analysis was approved by the Northwest and
Central Switzerland Ethics Committee (EKNZ-2018-01156).
Treatment Characteristics
For treatment planning, computed tomography was car-
ried out and all patients were immobilised with a body cast.Please cite this article as: Walser M et al., Clinical Outcome of Sacral Cho
Clinical Oncology, https://doi.org/10.1016/j.clon.2021.07.012Preoperative and postoperative magnetic resonance images
(MRI) were usually fused with the planning computed to-
mography scan. The gross tumour volume (GTV) included
the resection cavity, gross residual tumour if any. The clinical
target volume (CTV1) defining the first dose level encom-
passed the GTV, surgical tract and areas of microscopic
tumour spread. CTV1 was expanded by 1 cm to the GTV
adapted to anatomical borders. The CTV2 included the GTV
andwas treated as the boost volume either in a sequential (n
¼ 51, 85%) or a simultaneous integrated boost (SIB; n ¼ 9,
15%) delivery paradigm. The planning target volume
included a 7 mm margin to account for set-up/range un-
certainty. In-house planning software (PSIplan)was used for
treatment planning, as described previously [14]. Patients
received definitive or adjuvant radiation therapy to total
doses ranging from 60.0 to 77.0 Gy(RBE) (median 74) with
single-fraction doses from1.8 to 3.0 Gy(RBE) (median 2) (see
Supplementary Table S1 for fractionation details). For
logistical reasons, some patients received combined
photoneproton radiation therapy (n ¼ 10, 17%). More spe-
cifically,most (n¼ 6; 60%) caseswere referred to PSI in order
to deliver only the radiation boost with protons. Two pa-
tients were treated with photons as no immediate proton
treatment slots were available. In another two patients it
was necessary to treat a small number of fractions with
photons due to a proton therapy interruption caused by a
major technical issue with the cyclotron. As such, the range
of total photon doses delivered to these patients was indeed
very different (2e54 Gy). For proton therapy, PBS proton
therapy only was delivered. Five (8%) patients with large
inoperable tumours received concomitant hyperthermia up
to 6 weekly sessions. We reported these results and the
treatment details recently [25]. During the median overall
treatment time of 49 days (range 41e67), all patients
received the total dose prescribed.
Follow-up
Follow-up was carried out by PSI and/or the referring
physicians with clinical and MRI controls every 6 months
within the first 2 years after proton therapy and then yearly
thereafter. Patient data were reviewed regularly by the
entire clinical team to characterise disease status as well as
toxicity in a weekly follow-up meeting. Acute toxicities
were defined as those adverse events that occurred from
the first day to day 90 after treatment, and all side-effects
occurring from day 90 onwards were defined as late toxic-
ities. Adverse events were graded based on the US National
Institutes of Health CTCAE grading system v5.0 [26].
Statistical Analysis
Actuarial time to event rates were calculated using the
KaplaneMeier method. The time to local failure, distant
metastasis, date of death and toxicity higher than grade 2
were determined from the first day of proton therapy. The
first imaging or biopsy showing local or distant recurrence
was the event for local control or distant metastasis, and
death was the event defining overall survival. The date ofrdoma Patients Treated with Pencil Beam Scanning Proton Therapy,
Table 1
Patient and disease characteristics (n ¼ 60)
Age at start of proton therapy (years)






For recurrent disease 13 (22)
Type of surgery n (%)
Gross total resection 33 (55)
Subtotal resection 17 (28)
None (biopsy only) 10 (17)
Tumour extension n (%)
Restricted to bone 11 (18)
Into bone and soft tissue 49 (82)





Metal implants n (%)
Yes 1 (2)
No 59 (98)
Proton therapy n (%)
Definitive 10 (17)
Postoperative 50 (83)
Treatment modality n (%)
Proton only 50 (82)
Proton and photon mixed 10 (17)
Proton therapy combined with hyperthermia n (%)
Yes 5 (8)
No 55 (92)
Delivered dose in Gy(RBE) Median (range)
Total dose 74 (60e77)
Single fraction dose 2 (1.8e3)
Fractions 37 (20e41)
Irradiated volume (ml) 191 (0e1141)
M. Walser et al. / Clinical Oncology xxx (xxxx) xxx 3examination during follow-up revealing no toxicity higher
than grade 2 determined freedom from high-grade toxicity-
free survival. The Log-rank test was used to evaluate the
event end points for local control, freedom from distant
metastases, overall survival and freedom from grade 3
toxicity. A P < 0.05 was considered statistically significant.
Multivariate analyses were carried out using Cox propor-
tional hazards models in variables with a P value <0.1
revealed in univariate analyses. A stepwise backward selec-
tion method (criterion for removal: P < 0.05) was applied.
Analyses were carried out with JMP (version 14.0.2; SAS
Institute, Cary, NC, USA).Results
Control Rates
After a median follow-up time of 48 months (range
4e186), 20 (33%) recurrences were observed. NoteworthyPlease cite this article as: Walser M et al., Clinical Outcome of Sacral Cho
Clinical Oncology, https://doi.org/10.1016/j.clon.2021.07.012was that seven (35%) patients failed after 5 years and two
other treatment failures were observed 10 and 12 years
after proton therapy. Local recurrence/progression only and
distant failure only were observed in 12 and two patients,
respectively. For the remaining eight patients, two local
recurrence occurred before distant, and two distant re-
currences occurred before local recurrence, whereas for
four other patients, treatment failure was concomitant
locally and distantly (Table 2). Distant metastases occurred
in the lung in eight of 10 patients (Table 2). Themedian time
to local and distant failure was 48 months (range 2e146)
and 48.5 months (range 8e186), respectively. The 4-year
local control and DMFS were 77% (95% confidence interval
63e88) (Figure 1) and 89% (95% confidence interval 75e95),
respectively.
Six patients (10%) died of tumour progression and four
other patients (7%) died of non-chordoma-related causes
(i.e. bladder carcinoma, other unknown malignancy,
myocardial infarction and complications of an orchitis or
concomitant to this illness). The 4-year overall survival was
85% (95% confidence interval 70e93).Prognostic Factors
On univariate analysis, a significantly improved rate of
local control was associated with gross total resection (P ¼
0.02, hazard ratio 0.33; 95% confidence interval 0.13e0.85),
no tumour extension beyond the bone (P ¼ 0.013, hazard
ratio 0.11; 95% confidence interval 0.01e0.85) (Figure 2) and
GTV smaller than 130 ml (P ¼ 0.04, hazard ratio 2.59; 95%
confidence interval 0.99e6.77). On multivariate analysis,
tumour restricted to bone (P ¼ 0.0035) and gross total
resection (0.018) were the only significant independent
factors associated with a significant improved local tumour
control (Table 3). No significant factors were identified for
freedom from distant metastases and overall survival. A
trend towards statistical significance for overall survival
was observed for gross total resection versus subtotal
resection or biopsy (P ¼ 0.052, hazard ratio 0.28; 95% con-
fidence interval 0.07e1.11), tumour restricted to bone (P ¼
0.052) and GTV smaller than 130 ml (P ¼ 0.07, hazard ratio
2.97; 95% confidence interval 0.86e10.3) (Table 3). Of note,
there was a suggestion of better local control with hypo-
fractionation, although this did not reach statistical signif-
icance (P ¼ 0.07).Toxicities
Acute grade 3 skin toxicity with moist desquamation in
non-skin folds was observed in four (7%) patients. No acute
grade 4 toxicities were observed. Late grade 3 toxicity was
observed in five (5%) patients: sacral insufficiency fractures
and neuropathic pain interfering with activities of daily life
were observed in two and one patients, respectively. Two
(3%) patients developed secondary malignancies (grade 4, n
¼ 1; grade 5, n ¼ 1) in the bladder, 3 and 7 years after the
completion of radiation therapy. Of note, both patients
received a combination of photon and proton therapy (Tablerdoma Patients Treated with Pencil Beam Scanning Proton Therapy,
Table 2
Characteristics of patients with recurrent disease
RN Patient Concomitant recurrence Local failure Onset (months) Distant failure Onset (months) Location of distant failure
1 Yes Yes 42 Yes 42 Bone, lung
2 No Yes 69 Yes 57 lung
3 No Yes 122 No - -
4 No Yes 43 No - -
5 Yes Yes 37 Yes 37 Bone, liver, lung
6 No Yes 24 No - -
7 No Yes 56 No - -
8 No Yes 29 Yes 71 Lung, soft tissue
9 No Yes 17 No - -
10 No Yes 71 No - -
11 No Yes 41 No - -
12 Yes Yes 55 Yes 55 Lung
13 No Yes 53 No - -
14 No Yes 2 No - -
15 No Yes 18 Yes 15 Liver, lung
16 No Yes 76 No - -
17 No Yes 146 No - -
18 Yes Yes 80 Yes 80 Bone, liver, lung
19 No Yes 19 No - -
20 Yes Yes 81 Yes 81 Lung
21 No No - Yes 4 Skin
22 No No - Yes 26 Bone
M. Walser et al. / Clinical Oncology xxx (xxxx) xxx44). The 4-year toxicity-free survival was 91% (95% confi-
dence interval 79e97) (Figure 3).Discussion
High-dose particle therapy combined with surgery, when
functionally feasible, is considered as standard treatment for
sacral chordoma, based on published results from various
institutions worldwide. With particle therapy, safe dose
escalation is feasible while sparing pelvic critical structures
and thereforeminimising the likelihoodof radiation-induced
toxicity. Thepresent study reported a4-year local control rate
of 77% after proton therapy in a cohort comprising 45% of
patients with inoperable or subtotal resected sacralFig 1. Local control in sacral chordoma patients (n ¼ 60).
Please cite this article as: Walser M et al., Clinical Outcome of Sacral Cho
Clinical Oncology, https://doi.org/10.1016/j.clon.2021.07.012chordoma treated at diagnosis or for recurrent disease (Table
1). These outcomes are in line with other publications using
protons [15,16]. Sacral chordoma treated with adjuvant pro-
ton therapy after gross total resection showed a significantly
better local control rate than those in inoperable patients or
those with subtotal resection and partial resection (Table 4).
As such, it would be recommended to pursue aggressive
surgical management, with staged surgery procedures, prior
to proton therapy. It has been PSI’s management policy to
propose re-intervention if the tumour geometry and/or the
residual tumour is too large.Weneed to convince our surgical
colleagues, neurosurgeons and orthopaedists alike to
consider additional surgical staged procedures for what is
perceived in the surgical community as a ‘benign’ disease.
However, we have been only partially successful, as attestedFig 2. Four-year >grade 2 toxicity rate.
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Table 3
Univariate and multivariate analysis
Univariate analysis Local control FFDR Overall survival
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age in years (median ¼ 59) >65 0.75 (0.22e2.66) 0.67 1.13 (0.23e5.52) 0.88 2.10 (0.54e8.21) 0.27
>50 1.15 (0.46e2.84) 0.77 1.29 (0.36e4.66) 0.70 1.98 (0.51e7.68) 0.31
>40 1.08 (0.36e3.29) 0.89 2.32 (0.29e18.5) 0.41 1.01 (0.21e4.77) 0.99
Sex male versus female 1.09 (0.43e2.74) 0.86 1.37 (0.35e5.32) 0.65 0.69 (0.19e2.47) 0.57
Oncologic surgery prior PT yes versus no 1.24 (0.16e9.84) 0.83 0.53 (0.06e4.81) 0.57 0.32 (0.04e2.78) 0.28
Total no. surgeries >median_(>1) 1.36 (0.53e3.46) 0.52 1.13 (0.29e4.43) 0.86 0.97 (0.25e3.81) 0.97
Interval 1st surgery to PT >median_(5 months) 1.46 (0.58e3.69) 0.42 1.48 (0.40e5.56) 0.56 0.91 (0.26e3.19) 0.88
>2 months 1.02 (0.13e7.92) 0.98 n/a 0.48 n/a 0.46
>12 months 1.77 (0.68e4.61) 0.24 1.35 (0.33e5.46) 0.73 1.43 (0.40e5.15) 0.58
Interval last surgery to PT >median_(>4 months) 1.37 (0.54e3.52) 0.51 0.93 (0.25e3.47) 0.91 1.40 (0.39e5.02) 0.60
>2 months 0.77 (0.25e2.37) 0.65 0.69 (0.14e3.37) 0.64 0.91 (0.19e4.31) 0.90
>12 months 2.68 (0.75e9.64) 0.12 1.44 (0.17e12.0) 0.73 0.81 (0.10e6.44) 0.84
Gross total resection yes versus STR or biopsy 0.33 (0.13e0.85) 0.0210* 0.34 (0.09e1.24) 0.09 0.28 (0.07e1.11) 0.05
Biopsy only yes versus GTR or STR 0.81 (0.10e6.41) 0.84 1.87 (0.21e16.8) 0.57 3.10 (0.36e26.7) 0.28
Tumour extension
restricted to bonyee
yes versus no 0.11 (0.01e0.85) 0.013* 0.22 (0.03e1.84) 0.13 n/a 0.05
PT treatment for a recurrence yes versus no 2.09 (0.83e5.25) 0.11 1.85 (0.51e6.62) 0.34 2.09 (0.60e7.29) 0.24
PT with hyperthermia yes versus no n/a 0.53 n/a 0.66 n/a 0.88
PT with photons mixed yes versus no 1.02 (0.33e3.11) 0.98 n/a 0.10 1.46 (0.37e5.67) 0.59
Hypofractionated PT yes versus no 2.84 (0.88e9.09) 0.07 1.25 (0.15e10.6) 0.83 3.12 (0.63e15.6) 0.14
GTV >130 ml ¼ mean 2.59 (0.99e6.77) 0.04* 2.93 (0.81e10.6) 0.09 2.97 (0.86e10.3) 0.07
>0 ml ¼ median 2.17 (0.85e5.53) 0.10 2.59 (0.73e9.26) 0.13 2.09 (0.59e7.43) 0.24
>200 ml 1.86 (0.66e5.25) 0.24 2.19 (0.56e8.58) 0.25 1.70 (0.43e6.66) 0.44
>300 ml 1.27 (0.36e4.43) 0.71 1.64 (0.34e7.82) 0.53 1.50 (0.31e7.20) 0.61
Multivariate analysis (backwards elimination)
Model 1: Tumour extension restricted to bone
Hypofractionated PT yes versus no 1.15 (0.26e5.13) 0,86 n/a n/a
Tumour extension restricted
to bonyee
yes versus no 0.11 (0.01e0.85) 0.0035* n/a n/a
Model 2: Gross total resection
Hypofractionated PT yes versus no 1.69 (0.49e5.80) 0,75 n/a n/a
Gross total resection yes versus no 0.33 (0.13e0.85) 0.0181* n/a n/a
Model 3: GTV
Hypofractionated PT yes versus no 1.07 (0.22e5.13) 0.94 n/a n/a
GTV >130 ml ¼ mean 2.59 (0.99e6.77) 0.06 n/a n/a
CI, confidence interval; FFDR, freedom from distant recurrence; GTR, gross total resection; GTV, gross tumour volume; HR, hazard ratio; PT,
proton therapy; STR, subtotal resection.
* Statistically significant.
M. Walser et al. / Clinical Oncology xxx (xxxx) xxx 5by the small number of staged surgical procedures (Table 1).
Similar resultswere reported from theBoston group [15]. The
5-year local tumour control rate in their series of primarily
operated andadjuvant irradiatedpatientswithR0/1was86%,
whereas the patients treated with radiation therapy alone
had a local control rate of only 50%. Additionally, in a later
study, the same group analysed the outcome in a larger
cohort of operated patients where they observed a trend
towards improved local control in R0/1 compared with R2
margin status [27]. They correlated en bloc resection with a
higher probability of gross total tumour removal, leading to
significantly better 5-year local control rates with this pro-
cedure than in patients with an intralesional operation. Our
investigation analysing the extension of the tumour
discriminating between restriction of the chordoma to the
bone and an additional extraosseous component with orPlease cite this article as: Walser M et al., Clinical Outcome of Sacral Cho
Clinical Oncology, https://doi.org/10.1016/j.clon.2021.07.012without infiltration into surrounding tissue and organs led to
significant differences in local control rates in multivariate
analysis (Table 4). The analysis of dependence of tumour
volume affecting local control rate showed that the GTV is a
significant prognostic factor for local control,with a cut-off of
130 ml (Table 3) on univariate analyses. Other groups have
also shown that tumour size is a predictor for better overall
survival [18,27]. Of note, the observed suboptimal local
tumour outcome for large/inoperable tumours led to a
change in our proton treatment fractionation for these
challenging tumours. We implemented a SIB concept with
hypofractionation based on the excellent tumour control
rates in other published studies usinghypofractionationwith
protons aswell aswith heavy ions [18,28]. Retrospective data
of 23 patients of primaryand recurrentmacroscopic tumours
treated at Hyogo Ion Beam Medical Center in Japan withrdoma Patients Treated with Pencil Beam Scanning Proton Therapy,
Table 4
Tumour morbidity and toxicity*
Tumour morbidity Acute toxicity Late toxicity
n (%) n (%) n (%)
Tumour mass swelling 5 (9) na na
Pain/sensoric/motoric 6 (10) 9 (17) 12 (20)
Gastrointestinal 7 (12) 10 (18) 7 (12)
Genitourinary 6 (10) 4 (7) 0 (0)
General condition na 2 (4) 0 (0)
Dermatitis na 51 (94) 0 (0)
Fibrosis na na 10 (17)
Pigmentation na na 10 (17)
Bone fracture na na 5 (8)
Second malignancy 2 (3)
Grade 0 na 1 (2) 26 (43)
1 na 22 (37) 12 (20)
2 na 26 (43) 18 (30)
3 na 6 (10) 3 (5)
4-5y 2 (3)y
Missing na 5 0
* According to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.
y Second malignancy grade 4 in one and 5 in another patient.
Fig 3. Tumour extension regarding restriction to bone (yes versus
no).
M. Walser et al. / Clinical Oncology xxx (xxxx) xxx6protons and carbon ion showed a 3-year local control rate of
94% delivering 70.4 Gy(RBE) in either 16 or 32 fractions.
Likewise, NIRS in Chiba published data of 188 patients irra-
diated formedically unresectable chordoma in 16 fractions to
total doses of 64.0e70.4 Gy(RBE). The 5-year local control
rate was 77.2%. At the Heidelberg Ionbeam-Therapy Center,
the carbon ion treatmentof 56patientswith sacral chordoma
was retrospectively analysed [29]. Thirty-three patients
received carbon ion onlywith single doses of 3 Gy(RBE) up to
total doses of 60e66 Gy(RBE). The other 23 patients received
a carbon ion boost of 15e24 Gy(RBE) with single doses of 3
Gy(RBE) after normofractionated intensity-modulated
radiotherapy of 50e52 Gy. The local control rate after 3
years was 53%. There was no significant difference in local
control regarding dose or fractionation scheme. The nine
patients in our study who were treated with a SIB concept
received single doses of either 3 Gy(RBE) up to 60 Gy(RBE) or
2.5 Gy(RBE) to 70 Gy(RBE). The five most recently treated
patients receivedadditional hyperthermia therapycombinedPlease cite this article as: Walser M et al., Clinical Outcome of Sacral Cho
Clinical Oncology, https://doi.org/10.1016/j.clon.2021.07.012with hypofractionated proton therapy [25]. On univariate
analysis, we observed a trend towards better local control for
patients treated with hypofractionation compared with
normofractionated regimens in patients with unresectable
disease. The use ofmoderate hypofractionation did not result
in a significantly higher toxicity rate, regarding gastrointes-
tinal or neurotoxicity (Table 3). The grade 3 toxicity observed
in 2/8 patients treated with hypofractionation as well as the
grade 4 skin toxicity reported from NIRS in their analysis
highlight that the use of hypofractionation has to be well
assessed and caution is warranted in the delivery of higher
daily fractions. The rate of higher-grade toxicities in our
cohort overall was moderate and comparable with the rates
in other studies using normofractionated proton therapy.
Higher-grade acute toxicity was limited to grade 3 skin
toxicity in three patients (5%).
The analysis from Boston with proton therapy and Hei-
delberg with heavy ions both showed worse outcome
regarding local control in recurrent sacral chordomas
[15,29]. Thirteen (22%) of our patients were treated after
local recurrence of the chordoma. Twelve of these patients
were reoperated on (seven with one and five with two
reoperations). In our analysis there was no significant dif-
ference regarding local control for these patients (P ¼ 0.11).
Regarding treatment technique, it is advisable to irra-
diate sacral chordomas exclusively with a posterior beam
arrangement with two to three fields. This guarantees the
highest plan robustness conditions and avoidance of dose
in pelvic organs (i.e. over-shooting). However, this results
in an increase in the integral dose in the skin and the soft
tissue covering the sacral region. Higher-grade skin
toxicity was also reported in the abovementioned high
dose hypofractionated particle series [16,18,28]. Regarding
late higher-grade toxicities observed at PSI, two (3%) pa-
tients developed fractures of involved bone requiringrdoma Patients Treated with Pencil Beam Scanning Proton Therapy,
M. Walser et al. / Clinical Oncology xxx (xxxx) xxx 7surgical intervention after proton therapy. In the analysis
of the irradiated sacral chordoma patients from the Bos-
ton group, a substantial rate of sacral insufficiency frac-
tures was also reported [30]. Importantly, bladder cancer
was diagnosed 3 and 7 years after the completion of
proton therapy in our series. Of note, both had combined
photon/proton treatment with photon doses of 45 Gy and
54 Gy. One patient died as a result of his secondary ma-
lignancy. Different studies have investigated the rate of
occurrence of bladder carcinoma and other second ma-
lignancies after photon therapy to the pelvis. Of prime
interest are the studies where only radiation therapy and
no chemotherapy was used, as in prostate cancer treat-
ment. In their review, Suriano et al. [31] showed the re-
sults from different studies investigating the occurrence
of bladder cancer after radiation therapy for prostate
cancer and found an elevated risk. Interestingly, Weber
et al. [32] has shown that most of the diagnosed sec-
ondary malignancies that occur in the gastrointestinal
tract in irradiated prostate cancer patients develop in
areas that receive below the Gy unit. Although the
occurrence of a secondary malignancy by a solid tumour 3
years after radiation therapy in our patient is early, in the
study of Shirodkar et al. [33] the mean latency from ra-
diation to diagnosis of bladder cancer was 5.5 years.
Regarding the fact that all criteria for a radiation-induced
malignancy in our two patients were fulfilled [34], we
considered these two cancers to be radiation-induced.
Finally, it is noteworthy that a fair percentage of patients
(35%) failed after 5 years and treatment failures were
observed 10 and 12 years after PBS proton therapy in two
patients. For clinical follow-up, these results are important,
and they indicate a non-trivial level of recurrence in a
population in which only a minority of patients receive
follow-up by a specialist. As such, long-term clinical and
imaging follow-up is needed. At PSI, we recommend annual
MRIs for 5 years (every 6 months within the first 2 years
after proton therapy) after PBS. From this time point until 10
years we recomment a MRI every two years (individual
discussions with patients thereafter) after the management
of chordoma, bearing in mind that this follow-up strategy
would not have detected one (5%) recurrence in our cohort.Conclusions
The results of this retrospective analysis of patients with
resectable and non-resectable sacral chordomas treated
with high dose PBS proton therapy is encouraging, with
good tumour control and a low probability of late high-
grade radiation-induced toxicity in most chordoma pa-
tients. Both the gross total resection and the tumour
restricted to the bone were independent predictors of local
tumour control. There was a suggestion of better local
control with hypofractionation, with or without hyper-
thermia, although this did not reach statistical significance,
in large inoperable sacral chordomas. This strategy will be
pursued in a multi-institutional pilot study involving the
USA, the Netherlands and Switzerland.Please cite this article as: Walser M et al., Clinical Outcome of Sacral Cho
Clinical Oncology, https://doi.org/10.1016/j.clon.2021.07.012Conflicts of Interest
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